Conventional and Kampo medicine in the treatment of mild to moderate COVID-19: A multicenter, retrospective observational study protocol by the Integrative Management in Japan for Epidemic Disease (IMJEDI study-Observation)

Shin Takayama*, Masayuki Kashima, Takao Namiki, Takashi Ito, Rie Ono, Ryutaro Arita, Natsumi Saito, Hajime Nakae, Yasuhito Irie, Seiichi Kobayashi, Tetsuhiro Yoshino, Tomoaki Ishigami, Koichiro Tanaka, Tatsuya Nogami, Satoko Minakawa, Mahiko Nagase, Akihiko Kashio, Tatsuya Ishige, Hirofumi Maehara, Toshiaki SaitoSadahiro Sempuku, Mayuko Yamazaki, Eiichi Tahara, Norio Suda, Kayo Nakamoto, Tadamichi Mitsuma, Hiroko Sato, Osamu Shimooki, Yoshinobu Nakada, Shuichi Abe, Takuya Masuda, Hiroki Kai, Kenichi Yokota, Shigeki Chiba, Fumihiro Saitoh, Yutaka Tanaka, Sayaka Koizumi, Susumu Fujii, Rie Katori, Mosaburo Kainuma, Kotaro Nochioka, Shih Wei Chiu, Akiko Kikuchi, Tomoko Suzuki, Masaru Mimura, Takuhiro Yamaguchi, Tadashi Ishii

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Fingerprint

Dive into the research topics of 'Conventional and Kampo medicine in the treatment of mild to moderate COVID-19: A multicenter, retrospective observational study protocol by the Integrative Management in Japan for Epidemic Disease (IMJEDI study-Observation)'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science